CONMED Co. (NYSE:CNMD – Get Free Report) has received an average rating of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $120.43.
Several equities research analysts recently weighed in on the stock. Wells Fargo & Company cut their price objective on shares of CONMED from $107.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, February 1st. Piper Sandler decreased their price objective on shares of CONMED from $130.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 1st. Needham & Company LLC upped their target price on CONMED from $119.00 to $129.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Finally, JPMorgan Chase & Co. decreased their price target on CONMED from $135.00 to $115.00 and set an “overweight” rating on the stock in a research note on Thursday, February 1st.
Read Our Latest Research Report on CNMD
Institutional Trading of CONMED
CONMED Stock Performance
NYSE CNMD opened at $69.88 on Monday. CONMED has a 12-month low of $69.78 and a 12-month high of $138.47. The firm has a 50-day moving average price of $78.80 and a two-hundred day moving average price of $93.89. The company has a market capitalization of $2.15 billion, a P/E ratio of 34.25, a P/E/G ratio of 0.66 and a beta of 1.33. The company has a quick ratio of 0.96, a current ratio of 1.98 and a debt-to-equity ratio of 1.17.
CONMED (NYSE:CNMD – Get Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $1.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.11 by ($0.05). The company had revenue of $327.05 million for the quarter, compared to analyst estimates of $332.94 million. CONMED had a return on equity of 13.69% and a net margin of 5.18%. Analysts anticipate that CONMED will post 4.34 earnings per share for the current year.
CONMED Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, April 5th. Stockholders of record on Friday, March 15th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date was Thursday, March 14th. CONMED’s payout ratio is 39.22%.
About CONMED
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.
Recommended Stories
- Five stocks we like better than CONMED
- How to Use the MarketBeat Dividend Calculator
- High-Yield Texas Instruments Could Hit New Highs Soon
- There Are Different Types of Stock To Invest In
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Which Wall Street Analysts are the Most Accurate?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.